

## Human KL-6 ELISA

Cat. No.: PL1017

Enzyme Immunoassay for the quantitative determination of KL-6 in human serum, plasma and bronchoalveolar lavage fluid (BALF).


Interstitial lung diseases (ILD) are a group of lung disorders characterized by interstitial lung thickening. Krebs von den Lungen-6 (KL-6) is a 200 kDa glycoprotein that is predominantly expressed by damaged alveolar type II cells, and it has been proposed as a potential biomarker of different ILD.<sup>1</sup> KL-6 has profibrotic and anti-apoptotic effects on lung fibroblasts and reflects the degree and severity of alveolar epithelial injury. KL-6 is predictive biomarker useful in the clinical management of ILD patients, particularly in patients with severe fibrotic lung disorders.<sup>1</sup> Serum KL-6 levels were also found elevated in Rheumatoid Arthritis – Associated IDL patients, and the levels positively correlated with HRCT fibrosis score.<sup>2</sup>

### PRINCIPLE OF KL-6 ELISA

The microtiter plate is coated with the antibody specifically binding the KL-6. The human serum, plasma or BALF is incubated in the plate with the capture antibody.

The specimen is washed out and the specifically bound protein is incubated with biotin-labelled detection antibody. Following another washing step, Streptavidin-HRP conjugate is added into the well.

Unbound reagent is then washed out. Horseradish peroxidase (HRP) bound in the complex reacts with the chromogenic substrate (TMB) creating the blue colour. The reaction is stopped by addition of STOP solution (H<sub>2</sub>SO<sub>4</sub>). The absorbance values are measured at 450 nm (optionally 450/630 nm) and are proportional to the concentration of KL-6 in the specimen. The concentration of KL-6 in unknown samples is determined from the calibration curve which is created by plotting the absorbance values against the standard concentration values.



### KIT CONTENTS

Item	Qty.
Antibody Coated Microtiter Plate	96 wells
Biotin-labelled Antibody	13 mL
Streptavidin-HRP Conjugate	13 mL
Master Standard	1 vial
Quality Control A (human serum, lyophilized)	1 vial
Quality Control B (human serum, lyophilized)	1 vial
Dilution Buffer	2x13 mL
Wash Buffer 15x conc.	50 mL
Substrate Solution	13 mL
STOP Solution	13 mL

### MATERIAL REQUIRED BUT NOT SUPPLIED

1. Glassware and test tubes
2. Microtiter plate washer
3. Precision pipettes (various volumes) with tips
4. Orbital shaker
5. Microtiter plate reader capable of measuring absorbance at 450 nm or 450/630 nm with software for data generation

### WARNINGS AND PRECAUTIONS

1. For research use only
2. For professional laboratory use
3. The reagents with different lot numbers should not be mixed
4. To prevent cross sample contamination, use disposable labware and pipette tips
5. To protect laboratory stuff, wear protective gloves and protective clothing
6. The substrate solution should remain colourless, keep it protected from light
7. The test should be performed at standard laboratory conditions (temperature 25°C ± 2°C).

### STORAGE CONDITIONS

1. The kit must be stored at 2 – 8°C.
2. The opened components can be stored for one week at 2 – 8°C.

### PREPARATION OF REAGENTS

- Use new pipette tip for pipetting different reagents and samples to prevent cross-contamination.
- All reagents and samples should be allowed to reach the temperature 25°C ± 2°C.

### Preparation of Standards

Reconstitute lyophilized Human KL-6 Master Standard in Dilution Buffer, for the volume information see the Certificate of Analysis. Let it rehydrate for 15 min. The concentration of human KL-6 in Master Standard is 10 U/mL

Prepare set of Standard solution as follows:

Use the Master Standard to produce a dilution series (as below). Mix each tube thoroughly before the next transfer. The Dilution Buffer serves as Blank.

	Volume of Standard	Dilution Buffer	Concentration
Std1	Standard 10 U/mL (lyophilized)	See CofA	10 U/mL
Std2	300 µL of Std1	300 µL	5 U/mL
Std3	300 µL of Std2	300 µL	2.5 U/mL
Std4	300 µL of Std3	300 µL	1.25 U/mL
Std5	300 µL of Std4	300 µL	0.625 U/mL
Std6	300 µL of Std5	300 µL	0.156 U/mL
Blank	-	300 µL	0 U/mL

### Preparation of Quality Control A and B

Reconstitute the lyophilized human serum Quality Controls in deionized/distilled water, for the volume information see the Certificate of Analysis. Let the QCs rehydrate for 15 min and dilute them 1:200 prior to use, see Preparation of samples.

### Preparation of Wash Buffer 1x

Prepare a working solution of Wash Buffer by adding 50 mL of Wash Buffer 15x conc. to 700 mL of deionized/ distilled water (dH<sub>2</sub>O). Mix well. Store at 4°C for two weeks or at -20°C for long term storage.

### Preparation of samples

Human serum, plasma or BALF may be used with this assay. For long-term storage the samples should be frozen at minimum -70°C. Lipemic or haemolytic samples may cause false results.

Recommended dilution of samples is 1:200. It is recommended to use the two-step dilution.

Dilution A (10x) for both singlets and duplicates: 5 µL of samples + 45 µL of Dilution Buffer.

Dilution B (20x): 8 µL of Dilution A + 152 µL of Dilution Buffer, for singlets; 15 µL of Dilution A + 285 µL of Dilution Buffer for duplicates.

Do not store the diluted samples.

### ASSAY PROCEDURE

1. Prepare the reagents as described in the previous chapter.
2. Pipette 100 µL of set of Standards, Quality Controls, diluted Samples and Dilution Buffer = Blank into each well. Incubate for **1 hour** at 25°C ±2°C, shaking at 300 rpm.
3. Wash the wells 3-times with 1x Wash Buffer (350 µL/well). When finished, tap the plate against the paper towel to remove the liquid completely.
4. Pipette 100 µL of Biotin-labelled Antibody into each well. Incubate for **1 hour** at 25°C ±2°C, shaking at 300 rpm.
5. Wash the wells as described in point 3.
6. Pipette 100 µL of Streptavidin-HRP into each well. Incubate for **30 min** at 25°C ±2°C, shaking at 300 rpm.
7. Wash the wells as described in point 3.
8. Pipette 100 µL Substrate solution, incubate for **10 min** at 25°C ±2°C. Avoid exposure to the light during this step.
9. Pipette 100 µL of STOP solution.
10. Read the signal at 450 or 450/630 nm within 15 min.

### PERFORMANCE CHARACTERISTICS

Samples used in the tests were diluted 1:200 as recommended and assayed. The results are multiplied by the dilution factor.

#### 1. Sensitivity

The limit of detection, defined as a concentration of human KL-6 giving absorbance higher than absorbance of blank + 3 standard deviations, is better than 0.05 U/mL of sample.

#### 2. Precision

##### Intra-assay

Sample	Mean (U/mL)	SD	CV (%)
1	631	13.6	2.2
2	193	3.9	2.0

##### Inter-assay (Run – to – run)

Sample	Mean (U/mL)	SD	CV (%)
1	526	11.2	2.1
2	185	3.7	2.0

### 3. Accuracy

#### Dilution linearity

Sample	Dilution	Measured concentration (U/mL)	Expected concentration (U/mL)	Yield (%)
1		629	-	-
	2x	309	314	98
	4x	155	157	98
	8x	78	79	100
2		323	-	-
	2x	159	162	99
	4x	81	81	100
	8x	44	40	110


#### Spiking Recovery

Sample	Spike (U/mL)	Measured concentration (U/mL)	Expected concentration (U/mL)	Yield (%)
1	-	195	-	-
	500	737	695	106
	250	440	445	99
	62.5	266	257	103

#### Typical standard curve

The standard curve needs to be measured in every test. Most of the microplate reader can automatically calculate the analyte concentration using 4-parameter algorithm or alternative functions to fit the standard points properly. The concentrations need to be multiplied by the dilution factor, either automatically by reader or manually.

#### Human KL-6 Standard Curve



### RESOURCE

<sup>1</sup> Prisco D, Grifoni E. The role of KL-6 testing in patients with suspected venous thromboembolism. *Semin Thromb Hemost.* 2009 Feb;35(1):50-9. doi: 10.1055/s-0029-1214148. Epub 2009 Mar 23. PMID: 19308893.

<sup>2</sup> WELLS, P.S. (2007), Integrated strategies for the diagnosis of venous thromboembolism. *Journal of Thrombosis and Haemostasis*, 5: 41-50. <https://doi.org/10.1111/j.1538-7836.2007.02493.x>